PODD vs. ARWR

In the year-to-date period, PODD achieves a 24.39% return, which is significantly higher than ARWR's -16.44% return. Over the past 10 years, PODD has outperformed ARWR with an annualized return of 27.58%, while ARWR has yielded a comparatively lower 9.88% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Insulet Corporation (PODD) and Arrowhead Pharmaceuticals, Inc. (ARWR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PODD Sharpe Ratio is 1.87, which is higher than the ARWR Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of PODD and ARWR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither PODD nor ARWR has paid dividends to shareholders.

The maximum PODD drawdown since its inception was -90.28%, smaller than the maximum ARWR drawdown of -99.83%. Use the drawdown chart below to compare losses from any high point for PODD and ARWR. For additional features, visit the drawdowns tool.

Insulet Corporation (PODD) has a higher volatility of 20.88% compared to Arrowhead Pharmaceuticals, Inc. (ARWR) at 16.84%. This indicates that PODD's price experiences larger fluctuations and is considered to be riskier than ARWR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Insulet Corporation and Arrowhead Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.